Baxter Travenol Laboratories Hyland Therapeutics unit start human clinical trial genetically engineer Factor VIII clot agent miss blood hemophiliacs. It unlike Factor VIII concentrate currently genetically engineer Factor VIII limited availability human plasma completely free blood-borne virus include AIDS form hepatitis Baxter said. Baxter final U.S. clinical trial highly purify form Factor VIII derive human plasma produce use advanced process incorporate monoclonal antibody purification. It Genetics Institute publicly held biotechnology company Baxter shareholder supply protein human clinical test substantial portion ongoing production requirements. Reuter 